Business
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
WALTHAM, Mass., May 07, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its upsized underwritten public o
About this update from Viridian Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/46ca4556460647439c2ddf3bcc2d17f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.Fp27tiI9MhkihrP6Iir_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MA--/https://media.zenfs.com/en/business-wire.com/46ca4556460647439c2ddf3bcc2d17f1","width":960,"height":240},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RM.2ejnwTvDRo9pyM7LjfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MDA-/https://media.zenfs.com/en/business-wire.com/46ca4556460647439c2ddf3bcc2d17f1","width":1200,"height":300}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., May 07, 2026--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share (such offering, the "Equity Offering").","length":681,"tagName":"p"},{"type":"text","content":"Viridian estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be approximately $334.7 million, after deducting underwriting discounts and commissions and Viridian’s estimated offering expenses. In addition, Viridian has granted the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an additional $25.0 million aggregate principal amount of Convertible Notes offered in the Convertible Notes Offering, solely to cover over-allotments and on the same terms and conditions. Viridian also granted the underwriters of the Equity Offering a 30-day option to purchase up to an additional 1,102,941 shares of its common stock, on the same terms and conditions.","length":737,"tagName":"p"},{"type":"text","content":"The Convertible Notes Offering and the Equity Offering are expected to close on May 11, 2026, subject in each case t...